Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
Lack of infrastructure for identifying mutations and access routes is holding back use of targeted medicines in children with cancer
GSK looks to become a cancer contender once again, while Merck and Roche go toe-to-toe in TNBC.
Promising Phase II data mean it could be third time lucky for Roche in disease with no approved treatments.
Bill Anderson says Roche has scrapped budgets and improved productivity and re-energised teams. But is it too good to be true?
Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.
AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.